

# **Genetic and environmental influences on the transition from acute to chronic pain**

**Ze'ev Seltzer, DMD**

Professor of Genetics

Canada Senior Research Chair

University of Toronto CTR for the Study of Pain

# Presentation outline


- ❑ Pathophysiology of the transition from acute to chronic pain
- ❑ Comparative pain genetics
  - **Animal models**
- ❑ Heritability and genetic assays
- ❑ Expected gains for pain medicine

Brief update


Pathophysiology of the transition  
from acute to chronic pain

# What triggers the transition? - I

- Electrical signal (“Injury discharge”; online/msec)




# Injury discharge



2. Electrical shock  
to determine  
fiber class:  $A\beta$ - $\delta$ ; C


1. Noxious & nonnoxious  
stimuli



# Injury discharge

33% of cut C-fibers


25% of cut A-fibers



**Prolonged “saw tooth” type**


12% of cut afferents

Lasts hours



# Injury discharge triggers neuropathic pain - I


## Preemptive analgesia




Efficacy of preemptive analgesia in humans is debated in the literature

# What triggers the transition? - II

- Chemical signal(s) (Neurotrophic factors: e.g., NGF; hrs/days)





# Neuroplastic changes following nerve injury



PNS changes:

- **Neuroma formation**

# Neuroplastic changes following nerve injury




**Production of novel Na<sup>+</sup> channels**

**Assembly in neuroma and DRG**

**PNS changes:**

- Neuroma formation
- **Spontaneous firing**


# Neuroplastic changes following nerve injury




## PNS changes:

- Neuroma formation
- Spontaneous firing
- **Firing induced by**
  - chemical mediators (histamine, bradykinin...)
  - Mechanical stimuli (e.g., malfitting prosthesis)
  - electrical stimuli (cross-talk, ephapses)

# Neuroplastic changes following nerve injury (cont.)




# Neuroplastic changes following nerve injury (cont.)



## CNS changes:

- Loss of I° & II° / microglia reaction / astroglia
- Loss of receptors (e.g., opioid rec.)
- ↓↑ mediators + phenotypic switch (e.g., GABA depolarizes)

# Neuroplastic changes following nerve injury (cont.)




## CNS changes:

- Loss of I° & their terminals / microglia reaction / astroglia
- Loss of receptors (e.g., opioid rec.)
- ↓↑ mediators + phenotypic switch (e.g., GABA depolarizes)
- **Rewiring of the pain network:**
  - ⇔ tuning curves; novel modalities
  - ⇔ RFs
  - segmental disinhibition
  - central sensitization
  - reduced efficacy of descending inhibition



Comparative approach:

Animal models used in pain genetics


# Genetic selection based on spontaneous neuropathic pain



Devor and Raber 1990, 2005




# Neuropathic pain levels are strain specific / 2 species



$$\text{Var}_{\text{Pain}} = \text{Var}_{\text{Gen}} + \text{Var}_{\text{Env}}$$

*(Note: The Var<sub>Env</sub> term in the original image is crossed out with a blue X.)*


Seltzer & Shir (1998)



Seltzer et al (2001)



# Stimulus-evoked chronic pain is also determined genetically

## PSL model Partial Sciatic tight Ligation





# Pain abnormalities in the PSL model - I

Tactile allodynia:









# Pain abnormalities in the PSL model - II

Heat hyperalgesia:



# Acute pain - Tactile allodynia - Heat hyperalgesia - Spontaneous pain

## RATS (Mogil et al. in mice)




# Conclusions

1. **Acute** pain sensitivity does not predict levels of **chronic** pain (3 different chronic pain models, 2 stimulus modalities, 2 species, 2 research groups).
2. Levels of **spontaneous** chronic pain are not correlated with levels of **stimulus-evoked** chronic pain.
3. If these results are translatable to humans, **genes are 'syndrome-specific'**. Pharmaco-genetic solutions will have to be tailored per syndrome.

## Heritability of chronic pain

How much of the variance is accountable by genetics?

# Heritability in rodents



- Nociception: 30-76% mean ~ 53%
- Anti-nociception / analgesia: 23-68% mean ~ 45%
- Neuropathic pain (SNL, Autotomy, PSL): ~ 30-70% mean ~50%


# Heritability of pain in humans

Pedigree analyses / twins studies:  $h^2 \sim 0.2-0.7$  (mean  $\sim 50\%$ )

- Sciatica
- Diabetic neuropathy
- Carpal tunnel syndrome
- “Burning feet” syndrome
- Post-herpetic neuralgia (HLA)
- CRPS (HLA)
- Fibromyalgia (HLA; *5HTTP1*)
- Low back pain / Sciatica (*GCH1*; *BDNF*)
- Migraine (*Cacna1a*, *ATP1A2*, ...)
- TMD - Temporo-Mandibular Pain Disorder (*COMT*)
- Phantom limb pain / stump pain (HLA, *GCH1*, *GDNF*)
- Post-Mastectomy Pain Syndrome (*COMT*, *GCH1*)

Phenomics of chronic pain as a complex trait

Different genes for different phenotypes



# Chronic pain phenomics

## Choosing the right phenotypes for genetics:

- **Clinical relevance**
- **Mechanism-based**
- **N traits vs. multiple comparisons (“Bonferroni correction”)**
- **Pooling / Indexing / Loosing resolution**
- **Endophenotypes**

# The Human Pain Phenome Project

- Detailed registry of previous chronic pain episodes
- Aetiology and medical history
- Detailed phenotypes
- Tests (QST, electrodiagnosis, imaging, biochemistry)
- Treatment effects
- Additional traits: life style, personality / character
- Bioinformatics / data mining

Expected gains in pain genetics

- Diagnostic kits
- Prognostic kits
- Preventive pain medicine
- Novel painkillers
- New mechanisms
- Gene therapy
- Better animal models
- Faster / cheaper clinical trials

- Diagnostic kits
- Prognostic kits
- Preventive pain medicine
- Novel painkillers
- **New mechanisms**
- **Gene therapy**
- Better animal models
- Faster / cheaper clinical trials

- Diagnostic kits
- Prognostic kits
- Preventive pain medicine
- Novel painkillers
- New mechanisms
- Gene therapy
- **Better animal models**
- **Faster / cheaper clinical trials**

# United States Congress declared: 2001-2010: The Decade of Pain Control and Research

The Human Genome Project has developed methodological templates that can be transposed immediately to pain genetics.

This is the time to:

- Establish new research teams
- Support the collections of DNA samples / multicenter approach
- Finance genome-wide screens using microarray chips  
(1,000 samples X \$ 500/ sample = \$ 0.5 million / syndrome)




**Proposed goal for 2010:** First draft listing all major chronic pain genes in humans and mice.  
Given the right support – this is achievable !


Thank  
**Thank**  
**You!**  
THANK You  
Thank you

# Injury discharge triggers neuropathic pain - II


## Electrical tetanization



# Neuroplastic changes following nerve injury (cont.)




# Activity in neuroma and DRG causes pain



Resection / RF / neurolysis of painful neuroma & GG - sometime successful

Different genes for different phenotypes



Phenomics of chronic pain as a complex trait

# Chronic pain phenomics

## Choosing the right phenotypes for genetics:





- **Clinical relevance**
- **Mechanism-based**
- **N traits vs. multiple comparisons (“Bonferroni correction”)**
- **Pooling / Indexing / Loosing resolution**
- **Endophenotypes**

# The Human Pain Phenome Project

- Detailed registry of previous chronic pain episodes
- Aetiology and medical history
- Detailed phenotypes
- Tests (QST, electrodiagnosis, imaging, biochemistry)
- Treatment effects
- Additional traits: life style, personality / character
- Bioinformatics / data mining

# Acute pain - Tactile allodynia - Heat hyperalgesia - Spontaneous pain


## MICE



Mogil et al (1999)

Mogil et al (1999)

# Thousands/~25K genes in the human genome encode the chronic pain network



# Shall we need to control thousands to treat pain ?

## No


- Most genes have been fixed throughout evolution  
(e.g., “*Painless*” for noxious heat in the fly larva)
- While many have Single Nucleotide Polymorphisms (SNPs)
- Only a small fraction are functional, even fewer clinically relevant
- So how many will have to be treated to treat a given pain syndrome?

## Not known as of yet

Guess: ~5 ‘major’ and up to ~15 ‘modifiers’ per syndrome

How many genes would have to be  
pharmaco-genetically controlled to  
provide solutions for a pain syndrome?

# Neuroplastic changes following nerve injury (cont.)



# **Genetic and environmental influences on the transition from acute to chronic pain**

**Ze'ev Seltzer, DMD**


Professor of Genetics

Canada Senior Research Chair




University of Toronto CTR for the Study of Pain

# The case of Roni A. (male , age 44, contractor)

- 1995 - suffered an accident at work
  - L. brachial plexus avulsion
  - L. hand numb and painful
  - L. hand paralysed at an awkward position



- 1997 – surgical relocation of the arm
- 2002 – amputation of the hand
  - Telescoping
  - Triggering the phantom from the face/arm
  - Exacerbation of pain
    - When symp system aroused
    - Changing weather
    - When attempting to move phantom



# No therapy has helped Roni get rid of the pain

